| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On September 24, 2007 - Corrected Copy
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
|
|
| 1992P-0250
|
| Refrain from action against Genetic Systems HIV-1 test kits
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| 2002D-0081
|
| Hepatitis B Surface Antigen (HBSAG) Assays to Test Blood
|
|
|
|
|
| 2005H-0271
|
| Civil Money Penalty: TMJ Implants, Inc.
|
|
|
|
|
| 2005P-0405
|
| Reclassification for Metal/Metal Semiconstrained Hip Joint Prostheses with Cemented or Uncemented Acetabular Components
|
|
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
|
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| 2007N-0264
|
| Revisions to the Requirements Applicable to Blood, Blood Components and Source Plasma, Direct Final Rule
|
|
|
|
|
| 2007N-0330
|
| Presidential Interagency Working Group on Import Safety; Public Meeting
|
|
|
|
|
| 2007P-0097
|
| Issue a new regulation wine product the composition of wine , water, sugar, with or without flavorings and an alcohol content of less than 75% can not be marketed or sold with a wine varietal designa
|
|
|
|
|
|
|
|
|
| 2007P-0282
|
| Require all products labels to include this information: Products % Costs Packaging: 80% Content: 20%
|
|
|
|
|
| 2007P-0358
|
| Ensure the Safe and Effective Use of Orally Administered Immunosuppressant Drugs That are Used in the Transplant Population and are Characterized by a Narrow Therapeutic Index
|
|
| |
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
|
|
| EC 2424
|
| Mrs. Lisa Jaeck-Fisher
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2425
|
| Ms. DAnae Kesel
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2426
|
| Randall International LP
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2427
|
| Mr. John Marin
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2428
|
| FDA
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2429
|
| Mr. Donald Kiesling
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2430
|
| Mrs. Jo McClure
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2431
|
| ASHTABULA COUNTY MEDICAL CENTER
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2432
|
| Mrs. Deborah Blacher
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2433
|
| Mrs. Alicia Laddin
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2434
|
| Mrs. Maureen Hetrick
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2435
|
| Miss. HEIDI BALDWIN
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2436
|
| Mrs. Yelena Petrova
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2437
|
| Mrs. Genesis DeLong
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2438
|
| KINeSYS Inc.
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2439
|
| Mrs. jennifer helsdingen
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2440
|
| Mr. Jason Dawson
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2441
|
| University of Pennsylvania
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2442
|
| Mr. A Briscoe
|
| Vol #:
|
| 161
|
|
|
|
|
| EC 2443
|
| Miss. Kelly Ryan
|
| Vol #:
|
| 161
|
|
| | | | | | | | |
|
| |
|
| EC 2444
|
| Mr. Alex Ross
|
| Vol #:
|
| 161
|
|
|
|
|
| 1992P-0250
|
| Refrain from action against Genetic Systems HIV-1 test kits
|
|
|
|
|
| WDL 1
|
| Bourget Laboratories
|
| Vol #:
|
| 1
|
|
| |
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| LET 20876
|
| NOW Foods
|
| Vol #:
|
| 181
|
|
|
|
|
| 2002D-0081
|
| Hepatitis B Surface Antigen (HBSAG) Assays to Test Blood
|
|
|
|
|
| C 5
|
| ZLB Plasma
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005H-0271
|
| Civil Money Penalty: TMJ Implants, Inc.
|
|
|
|
|
| RBF 1
|
| TMJ Implants, Inc, and Robert W. Christensen and Maureen K. Mooney
|
| Vol #:
|
| 245
|
|
|
|
|
| 2005P-0405
|
| Reclassification for Metal/Metal Semiconstrained Hip Joint Prostheses with Cemented or Uncemented Acetabular Components
|
|
|
|
|
| LET 3
|
| FDA/CDRH to Orhopedic Surgical Manufacturers Association
|
| Vol #:
|
| 4
|
|
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
|
|
| C 18337
|
| G. Wright
|
| Vol #:
|
| 198
|
|
|
|
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
|
|
|
|
|
| C 2625
|
| P Ashton
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2626
|
| P Colombo
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2627
|
| W Fleming
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2628
|
| M Eaton
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2629
|
| H Moessner
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2630
|
| C Chumbly
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2631
|
| D Stafford
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2632
|
| A Tyler
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2633
|
| C DeLosa
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2634
|
| R. Chrzanowski
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2635
|
| L Dunaway
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2636
|
| J Whidden
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2637
|
| E Collinsworth
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2638
|
| V Feagell
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2639
|
| G Penick
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2640
|
| V Collins
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2641
|
| R Riegsecker
|
| Vol #:
|
| 27
|
|
|
|
|
| C 2642
|
| A Vamdergriff
|
| Vol #:
|
| 28
|
|
| | | | | | | | |
|
| |
|
| EC 114
|
| Association of Food and Drug Officials
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007P-0097
|
| Issue a new regulation wine product the composition of wine , water, sugar, with or without flavorings and an alcohol content of less than 75% can not be marketed or sold with a wine varietal designa
|
|
|
|
|
|
| |
|
|
|
| C 2
|
| DEER RUN WINERY
|
| Vol #:
|
| 1
|
|
|
|
|
| C 3
|
| Ciccone Vineyard & Winery LLC
|
| Vol #:
|
| 1
|
|
|
|
|
| C 4
|
| OAKS RANCH
|
| Vol #:
|
| 1
|
|
|
|
|
| C 5
|
| OWENS & SULLIVANS WINERY
|
| Vol #:
|
| 1
|
|
| |
|
| 2007P-0282
|
| Require all products labels to include this information: Products % Costs Packaging: 80% Content: 20%
|
|
|
|
|
| EC 61
|
| Mr. Yi Pan
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007P-0358
|
| Ensure the Safe and Effective Use of Orally Administered Immunosuppressant Drugs That are Used in the Transplant Population and are Characterized by a Narrow Therapeutic Index
|
|
|
|
|
|
|
|
|
|
|
| CP 1
|
| Astellas Pharma US, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| CP 2
|
| FDA/DDM to Astellas Pharma US, Inc.
|
| Vol #:
|
| 1
|
|
